PLEASANTON, Calif., May 6, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston. Leading and emerging biopharmas will share innovations and strategies to drive more coordinated customer engagement through effective use of AI and alignment across data, content, and teams.
Veeva CEO Peter Gassner will headline the opening keynote, sharing Veeva's major initiative to add AI to the Vault Platform and Veeva applications, including ongoing innovations across Veeva Commercial Cloud and Veeva Data Cloud.
Keynote presenters will include experiences from:
ANI Pharmaceuticals, Gamida Cell, NewAmsterdam Pharma, Orchard Therapeutics, Sobi, and others will also share go-to-market best practices for emerging biotechs at launch and beyond.
"By connecting sales, marketing, and medical, field teams can seamlessly work together to drive more effective, customer-centric experiences," said Matt Farrell, president of Veeva Commercial Cloud. "We're excited to bring the industry together to share ideas and advancements in AI and data and help lead this next phase of unified engagement."
Veeva Commercial Summit is one of the largest industry events in North America for commercial and medical affairs leaders. Life sciences industry professionals can register and see the full agenda at veeva.com/Summit.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Matilde Macieira-Kaufmann
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$287.72 |
Daily Change: | -3.14 -1.08 |
Daily Volume: | 583,026 |
Market Cap: | US$47.020B |
August 18, 2025 July 23, 2025 June 25, 2025 June 11, 2025 June 04, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load